These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 38717943)

  • 1. Advances in pharmacotherapies for cytomegalovirus infection: what is the current state of play?
    Monday LM; Keri V; Chandrasekar PH
    Expert Opin Pharmacother; 2024 Apr; 25(6):685-694. PubMed ID: 38717943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Perspectives on Letermovir and Maribavir for the Management of Cytomegalovirus Infection in Solid Organ Transplant Recipients.
    Razonable RR
    Drug Des Devel Ther; 2024; 18():3987-4001. PubMed ID: 39258274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maribavir, brincidofovir and letermovir: Efficacy and safety of new antiviral drugs for treating cytomegalovirus infections.
    Frange P; Leruez-Ville M
    Med Mal Infect; 2018 Dec; 48(8):495-502. PubMed ID: 29650261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Refractory/Resistant Cytomegalovirus Infection in Transplant Recipients: An Update.
    Royston L; Papanicolaou GA; Neofytos D
    Viruses; 2024 Jul; 16(7):. PubMed ID: 39066247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Letermovir and Maribavir for the Treatment and Prevention of Cytomegalovirus Infection in Solid Organ and Stem Cell Transplant Recipients.
    Imlay HN; Kaul DR
    Clin Infect Dis; 2021 Jul; 73(1):156-160. PubMed ID: 33197929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic and immunologic management of cytomegalovirus infection after solid organ and hematopoietic stem cell transplantation.
    Meesing A; Razonable RR
    Expert Rev Clin Pharmacol; 2018 Aug; 11(8):773-788. PubMed ID: 30009675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Letermovir for the prevention of cytomegalovirus infection in adult cytomegalovirus-seropositive hematopoietic stem cell transplant recipients.
    Foolad F; Aitken SL; Chemaly RF
    Expert Rev Clin Pharmacol; 2018 Oct; 11(10):931-941. PubMed ID: 30004790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current and Emerging Antiviral Agents in the Prevention and Treatment of Cytomegalovirus in Pediatric Transplant Recipients.
    Valencia Deray KG; Danziger-Isakov LA; Downes KJ
    J Pediatric Infect Dis Soc; 2024 Feb; 13(Supplement_1):S14-S21. PubMed ID: 38417084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients.
    Avery RK; Marty FM; Strasfeld L; Lee I; Arrieta A; Chou S; Tatarowicz W; Villano S
    Transpl Infect Dis; 2010 Dec; 12(6):489-96. PubMed ID: 20682012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient.
    Jung S; Michel M; Stamminger T; Michel D
    BMC Infect Dis; 2019 May; 19(1):388. PubMed ID: 31068147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Letermovir as Salvage Therapy for Cytomegalovirus Infection in Transplant Recipients.
    Phoompoung P; Ferreira VH; Tikkanen J; Husain S; Viswabandya A; Kumar D; Humar A
    Transplantation; 2020 Feb; 104(2):404-409. PubMed ID: 32000236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emergence of letermovir resistance in solid organ transplant recipients with ganciclovir resistant cytomegalovirus infection: A case series and review of the literature.
    Hofmann E; Sidler D; Dahdal S; Bittel P; Suter-Riniker F; Manuel O; Walti LN; Hirzel C
    Transpl Infect Dis; 2021 Jun; 23(3):e13515. PubMed ID: 33210830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Efficacy and Safety of Different Antiviral Agents for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis.
    Gagelmann N; Ljungman P; Styczynski J; Kröger N
    Biol Blood Marrow Transplant; 2018 Oct; 24(10):2101-2109. PubMed ID: 29777868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New developments in the management of cytomegalovirus infection after solid organ transplantation.
    Eid AJ; Razonable RR
    Drugs; 2010 May; 70(8):965-81. PubMed ID: 20481654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Letermovir for the management of cytomegalovirus infection.
    Bowman LJ; Melaragno JI; Brennan DC
    Expert Opin Investig Drugs; 2017 Feb; 26(2):235-241. PubMed ID: 27998189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Letermovir successfully used for secondary prophylaxis in a heart transplant recipient with ganciclovir-resistant cytomegalovirus syndrome (UL97 mutation).
    Chong PP; Teiber D; Prokesch BC; Arasaratnam RJ; Peltz M; Drazner MH; Garg S
    Transpl Infect Dis; 2018 Oct; 20(5):e12965. PubMed ID: 29989279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating Real-World Experience With Maribavir for Treatment of Refractory/Resistant Cytomegalovirus in Renal Transplant Recipients.
    Beechar VB; Phadke VK; Pouch SM; Mehta AK; Karadkhele G; Larsen CP; Woodworth MH
    Clin Transplant; 2024 Oct; 38(10):e15480. PubMed ID: 39427300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Primary Letermovir Prophylaxis Versus Preemptive Antiviral Therapy for Cytomegalovirus on Economic and Clinical Outcomes after Hematopoietic Cell Transplantation.
    Tan CA; Palen L; Su Y; Li Y; Gennarelli RL; Perales MA; Cohen N; Papanicolaou GA; Shah GL; Seo SK
    Transplant Cell Ther; 2024 Aug; 30(8):792.e1-792.e12. PubMed ID: 38838781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Novelties for the management of cytomegalovirus after kidney transplantation].
    Kamar N; Marion O; Del Bello A
    Nephrol Ther; 2024 Aug; 20(4):269-276. PubMed ID: 39129511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Perspectives on Antimicrobial Agents: Maribavir.
    Halpern-Cohen V; Blumberg EA
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0240521. PubMed ID: 35916518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.